CERo Therapeutics Holdings, Inc. (CERO) began trading on the OTCQB market at 8:00 AM ET on December 2, 2025, after its Nasdaq listing was suspended for failing to meet minimum stockholders’ equity and bid‑price requirements. The move to OTCQB provides a new venue for investors while the company continues to pursue a Phase 1 clinical trial of its engineered T‑cell therapy, CER‑1236, for acute myeloid leukemia.
The Nasdaq delisting followed a series of financial challenges: the company has reported no revenue growth over the past three years, a negative earnings‑per‑share of –$102.61, and a low current ratio that signals liquidity pressure. The shift to OTCQB is a strategic response to these constraints, offering a less stringent listing environment and a platform for future capital‑raising efforts.
CER‑1236 has entered its second cohort with an increased dosage, and the first cohort completed without dose‑limiting toxicities. Progress in this trial is critical, as a successful outcome could unlock the company’s primary revenue driver and justify future investment. The company’s focus on this program underscores its intent to build a viable product pipeline despite limited cash flow.
In parallel, CERo has secured a new stock purchase agreement that could raise up to $14.6 million, part of a broader $25 million capital‑raising plan. The agreement is intended to support ongoing clinical development and bridge the company to the next funding milestone. Management views the OTCQB listing and the new financing as complementary steps to stabilize liquidity while advancing the therapeutic program.
CEO Chris Ehrlich said, “We remain committed to advancing CER‑1236 and to maximizing value for shareholders. The OTCQB listing provides a necessary liquidity platform as we continue to execute our long‑term strategy and pursue additional financing to support our clinical milestones.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.